Oncolysis and suppression of tumor growth by a GFP-expressing oncolytic adenovirus controlled by an hTERT and CMV hybrid promoter

Cancer Gene Therapy

Volumn 13, Issue 7, 2006, Pages 720-723

  Davis, J J ^a,b   Wang, L ^a   Dong, F ^a   Zhang, L ^a   Guo, W ^a   Teraishi, F ^a   Xu, K ^a   Ji, L ^a   Fang, B ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Adenovirus; E1A; Non small cell lung cancer; Telomerase; Virotherapy

Indexed keywords

ADENOVIRUS VECTOR; CRYSTAL VIOLET; E1A PROTEIN; GREEN FLUORESCENT PROTEIN; ONCOLYTIC VIRUS; TELOMERASE REVERSE TRANSCRIPTASE; VIRUS PROTEIN;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER THERAPY; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOTOXICITY; DOSE RESPONSE; FIBROBLAST; FLUORESCENCE MICROSCOPY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; STAINING; TRANSGENE; TUMOR CELL DESTRUCTION; TUMOR GROWTH; TUMOR XENOGRAFT; VIRAL GENE THERAPY; VIRAL GENETICS; VIRUS ACTIVATION; VIRUS INFECTIVITY; VIRUS REPLICATION; WESTERN BLOTTING;

ADENOVIRIDAE; ADENOVIRUS E1A PROTEINS; CELL LINE, TUMOR; CYTOMEGALOVIRUS; DNA-BINDING PROTEINS; GENE THERAPY; GREEN FLUORESCENT PROTEINS; HUMANS; NEOPLASM TRANSPLANTATION; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; PROMOTER REGIONS (GENETICS); TELOMERASE; TRANSPLANTATION, HETEROLOGOUS; VIRUS REPLICATION;

ADENOVIRIDAE; CYTOMEGALOVIRUS;

EID: 33747594748     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700944     Document Type: Article

References (10)

1. Li Y, Yu DC, Chen Y, Amin P, Zhang H, Nguyen N et al. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin. Cancer Res 2001; 61: 6428-6436.
2. Takahashi M, Sato T, Sagawa T, Lu Y, Sato Y, Iyama S et al. E1B-55K-deleted adenovirus expressing E1A-13S by AFP-enhancer/promoter is capable of highly specific replication in AFP-producing hepatocellular carcinoma and eradication of established tumor. Mol Ther 2002; 5: 627-634.
3. Yu DC, Chen Y, Dilley J, Li Y, Embry M, Zhang H et al. Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel. Cancer Res 2001; 61: 517-525.
4. Kurihara T, Brough DE, Kovesdi I, Kufe DW. Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J Clin Invest 2000; 106: 763-771.
5. Wu G, Deng W, Kundra V, Fang B, Roth JA, Ji L. A novel synthetic hTERT-Mini-CMV chimera promoter-driven tumor-selective and high-efficiency expression of transgene for systemic cancer gene therapy. Proc Am Assoc Cancer Res 2005; 46: 3358.
6. Gu J, Kagawa S, Takakura M, Kyo S, Inoue M, Roth JA et al. Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers. Cancer Res 2000; 60: 5359-5364.
7. Lin T, Gu J, Zhang L, Huang X, Stephens LC, Curley SA et al. Targeted expression of green fluorescent protein/tumor necrosis factor-related apoptosis-inducing ligand fusion protein from human telomerase reverse transcriptase promoter elicits antitumor activity without toxic effects on primary human hepatocytes. Cancer Res 2002; 62: 3620-3625.
8. Umeoka T, Kawashima T, Kagawa S, Teraishi F, Taki M, Nishizaki M et al. Visualization of intrathoracically disseminated solid tumors in mice with optical imaging by telomerase-specific amplification of a transferred green fluorescent protein gene. Cancer Res 2004; 64: 6259-6265.
9. Vigne E, Mahfouz I, Dedieu JF, Brie A, Perricaudet M, Yeh P. RGD inclusion in the hexon monomer provides adenovirus type 5-based vectors with a fiber knob-independent pathway for infection. J Virol 1999; 73: 5156-5161.
10. Sauthoff H, Pipiya T, Heitner S, Chen S, Norman RG, Rom WN et al. Late expression of p53 from a replicating adenovirus improves tumor cell killing and is more tumor cell specific than expression of the adenoviral death protein. Hum Gene Ther 2002; 13: 1859-1871.